Combo produces responses in triple-class refractory myeloma
Pediatric News ,
The most common grade 3/4 adverse events in this trial were thrombocytopenia (59%), anemia (44%), hyponatremia (22%), and…
塞利尼索：全新机制！为复发或难治多发性骨髓瘤患者带来临床获益
CN-Healthcare,
塞利尼索是一款靶向药，通过靶向XPO1来达到治疗疾病的目的。 多发性骨髓瘤(MM)是由骨髓浆细胞分化而来的恶性浆细胞瘤，发病机制尚不清楚，临床表现为骨髓浆细胞异常增生伴有单克隆免疫球蛋白(M蛋白)过度生成。据WHO统计，2020年中国有超过2.1万例新病例和…
Karyopharm Therapeutics: Promising Potential With 3 Ongoing Phase 3 Studies But Risky
Seeking Alpha,
Summary Selinexor has received three approvals but has faced disappointing sales due to competition and toxicity.
Current Frontline Treatment of Multiple Myeloma
Cancer Network,
ABSTRACT Treatment paradigms for management of newly diagnosed (ND) multiple myeloma have been evolving over the past 20 years…